

pDUO-hMD2/TLR4A

A plasmid coexpressing the human MD2 and TLR4A genes

Catalog code: pduo-hmd2tlr4a

<https://www.invivogen.com/pduo-md2-tlr4>

For research use only

Version 20H26-MM

PRODUCT INFORMATION

Contents

- 20 µg of pDUO-hMD2/TLR4A provided as DNA
- 2 x 1 ml blasticidin at 10 mg/ml

Storage and stability

- Product is shipped at room temperature.
- Upon receipt, store lyophilized DNA at -20°C.
- Resuspended DNA should be stored at -20°C.
- Store blasticidin at 4°C or -20°C. The expiry date is specified on the product label.

Quality control

- Plasmid construct has been confirmed by restriction analysis and sequencing.
- Plasmid DNA was purified by ion exchange chromatography and lyophilized.

GENERAL PRODUCT USE

Toll-Like receptors (TLRs) play a critical role in early innate immunity to invading pathogens by sensing microorganisms. These evolutionary conserved receptors, homologues of the Drosophila Toll gene, recognize highly conserved structural motifs only expressed by microbial pathogens, called pathogen-associated microbial patterns (PAMPs). PAMPs include various bacterial cell wall components such as lipopolysaccharides (LPS), peptidoglycans and lipopeptides, as well as flagellin, bacterial DNA and viral double-stranded RNA. Stimulation of TLRs by PAMPs initiates a signaling cascade that involves a number of proteins, such as MyD88 and IRAK. This signaling cascade leads to the activation of the transcription factor NF-κB which induces the secretion of pro-inflammatory cytokines and effector cytokines that direct the adaptive immune response.

To date ten human and twelve murine TLRs have been characterized, TLR1 to TLR10 in humans, and TLR1 to TLR9, TLR11, TLR12 and TLR13 in mice, the homolog of TLR10 being a pseudogene. In many instances, TLRs require the presence of a co-receptor to initiate the signaling cascade. One example is TLR4 which interacts with MD2 and CD14 to induce NF-κB in response to LPS stimulation.

pDUO is an expression vector designed to co-express two TLRs or TLR-related genes known to interact with each other. The genes cloned into pDUO comprise the coding sequence (without introns) from the ATG to the Stop codon.

PLASMID FEATURES

- **Human MD2 (480 bp) / Human TLR4A (2517 bp)** TLR4 is the receptor for Gram-negative lipopolysaccharide (LPS). The TLR4 gene was shown to be mutated in C3H/HeJ and C57BL/10ScCr mice, both of which are low responders to LPS. However, TLR4 alone is not sufficient to confer LPS responsiveness. TLR4 requires MD-2, a secreted molecule, to functionally interact with LPS^{1,2}. TLR4 physically associates with MD2, and together with a third protein called CD14, this complex is responsible for LPS recognition and signaling³.
- **hFerH and hFerL composite promoters:** Ferritin is a 24 subunit protein composed of two subunit types, termed H (heavy) and L (light), which perform complementary functions in the protein. Ferritin is ubiquitously expressed. Its synthesis is highly regulated by the iron status of the cell. The iron regulation is achieved at the translational level through the interaction between the iron-responsive element (IRE), located in the 5' untranslated region (5'UTR) of the ferritin mRNAs, and the iron regulatory protein⁴. To eliminate the iron regulation of the ferritin promoters, the 5'UTR of FerH and FerL have been replaced by the 5'UTR of the mouse and chimpanzee elongation factor 1 (EF1) genes, respectively.
- **SV40 enhancer** which is comprised of a 72-base-pair repeat allows the enhancement of gene expression in a large host range. The enhancement varies from 2-fold in non-permissive cells to 20-fold in permissive cells. Furthermore, the SV40 enhancer is able to direct nuclear localization of plasmids⁵.
- **CMV enhancer:** The major immediate early enhancer of the human cytomegalovirus (HCMV), located between nucleotides -118 and -524, is composed of unique and repeated sequence motifs. The HCMV enhancer can substitute for the 72-bp repeats of SV40 and is severalfold more active than the SV40 enhancer⁶.
- **SV40 pAn:** the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA. The efficiency of this signal was first described by Carswell *et al.*⁷
- **pMB1 ori:** a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.
- **FMDV IRES:** The internal ribosome entry site of the Foot and Mouth Disease Virus enables the translation of two open reading frames from one mRNA with high levels of expression⁸.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: info@invivogen.com

- **EM7** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*.
- **Bsr (blasticidin resistance gene):** The *bsr* gene from *Bacillus cereus* encodes a deaminase that confers resistance to the antibiotic Blasticidin. In bacteria, *bsr* is expressed from the constitutive *E. coli* EM7 promoter. In mammalian cells, *bsr* is transcribed from the human FerH composite promoter as a polycistronic mRNA and translated via the FMDV IRES.
- **EF1 pAn** is a strong polyadenylation signal. InvivoGen uses a sequence starting after the stop codon of the EF1 cDNA and finishing after a bent structure rich in GT.

METHODS

Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H₂O. Store resuspended plasmid at -20°C.

Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT116 or other commonly used laboratory *E. coli* strains, such as DH5α.

Blasticidin usage

Blasticidin should be used at 25-100 µg/ml in bacteria and 1-30 µg/ml in mammalian cells. Blasticidin is supplied at 10 mg/ml in HEPES buffer.

References

1. Shimazu R. et al., 1999. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. *J Exp Med*, 189(11):1777-82.
2. Nagai Y. et al., 2002. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. *Nat Immunol.* 3(7):667-72.
3. da Silva Correia J. et al., 2001. Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex transfer from CD14 to TLR4 and MD-2. *J Biol Chem*. 276(24):21129-35.
4. Eisenstein RS. & Munro HN. 1990. Translational regulation of ferritin synthesis by iron. *Enzyme* 44(1-4):42-58.
5. Dean DA. et al., 1999. Sequence requirements for plasmid nuclear import. *Exp. Cell. Res.* 253:713-22.
6. Boshart M. et al., 1985. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. *Cell* 141(2):521-30.
7. Carswell S. & Alwine JC. 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. *Mol. Cell Biol.* 10: 4248-4258.
8. Ramesh N et al., 1996. High-titer bicistronic retroviral vectors employing foot-and-mouth disease virus internal ribosome entry site. *Nucleic Acids Res.* 24(14):2697-700.

TECHNICAL SUPPORT


InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: info@invivogen.com



SdI (7)
CCTGCAGGGCTTACATAACTTACCGTAAATGGCCCGCTGGCTGACGCCCAACGACCCCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAA

NdeI (183)

101 **CGCCAATAGGGACTTCCATTGACGTCAATGGGTGGACTATTTACGTAACCTGCCACTTGGCACTACATCAACTGTATCATATGCCAAGTACGCC**
 201 **TATTGACGTCAATGACGGTAAATGGCCCGCTGGCATTATGCCAGTACATGACCTTATGGACTTCTACTTGGCACTACATCTACGTATTAGTCATC**
 301 **GCTATTACCATGATGATGCCGTTTGGCACTACATCAATGGCGTGGATAGCGGTTGACTCACGGGATTCCAAGTCTCCACCCCATTGACGTCAATG**
 401 **GGAGTTTGTGTTGACTAGTCAGGGCCCCAACCCCCCAAGCCCCATTACAACACGCTGGCGTACAGCGCGTACTTCCCCTGCTTGGGGCGG**

→

BspEI (522)

501 **GGCCTGAGACTCTATGCTCCGGATTGTCAGGCACGCCCTCGGCCCCGCCCTCGCCACCGCAGATTGGCGTAGGCCCTCCCGAGCGCCCTGCC**
 601 **TCCGAGGGCCGGCGACCATAAAAAGAAGCCGCCCTAGCCACGTCCCTCGCAGTTGGCGTCCCGGGCTGTCAGCTGCGCCAGAACACAGG**

→

701 **taagtgcgtgtgtttcccgccgtggctttacgggtatggcccttgctgccttgaattacttccatgcgcgtggctgcagttacgtgatc**
 801 **ttgatcccagagttcggttggaaagtggggagagttcgaggccttgcgcctaaggagcccttcgcctcgtgcgttgcggcggctggcgtggc**

PvuII (993)

901 **ctggggccgcgcgtgtaatctggggacccctcgccgtgtcgctgtcgtaagtctctagccataaaattttgtataaccagctgcgcac**
 1001 **ctttttctggcgagatagtctgtaaatgcggccaagatctgcacactggatttcgggtttttggggccggccggcgcacggggccgtgcgtccc**
 1101 **agccacatgttccggcaggccggcgtggagcggccaccgagaatcgacggggtagtctcaaaactggccgcctgcttgtgcctggcgtcg**
 1201 **gccgcgtgtatcgccccccctggggcgaaggctggccgggtcgccaccagttgcgtgagcggaaagatggccgttccggccctgtgcaggagc**

SmaI (1324)

1301 **tcaaaatggaggacgcggccggagacggccgggtgagtccacccacacaaggaaaaggcccccattccatccgtcgccatgtgactcca**

XbaI (1439)

1401 **cggagttaccggccgcgtccaggcacctcgattgtctcgagctttggagttacgtcgcttttaggttgggggggggtttatgcgtggatttcc**
 1501 **ccacactgagttggggactgaagagttggccagctggcacttgcattgtatcccttggatattggcccttttagttggatcttgcctcatc**
 1601 **tcaaggctcagacagttttttttccatttcagGTGCGTGAACACTACCCCTAAAGCCACCATGATGTCCTGCCTGGCTGG**

→ MetMetSerAlaSerArgLeuAlaGl

NcoI (1716)

1701 **GACTCTGATCCCAGCCATGGCCTTCCTCTCTGGTGAACGCCAAAGCTGGAGCCCTGCTGGAGGTGTTCTAATATTACTTATCAATGCATGGAG**
 9 yThrLeuI leProAlaMetAlaPheLeuSerCysValArgProGluSerTrpGluProCysValGluValValProAsnI leThrTyrGlnCysMetGlu

Bsu36I (1871)

1801 **CTGAATTCTACAAAATCCCCGACAACCTCCCTCTCAACCAAGAACCTGGACCTGAGCTTAATCCCTGAGGCTATTAGGCAGCTATAGCTTCTCA**
 43 LeuAsnPheTyrLysI leProAspAsnLeuProPheSerThrLysAsnLeuAspLeuSerPheAsnProLeuArgHisLeuGlySerTyrSerPhePheS
 1901 **GTTCCCAGAACTGCAGGTGCTGGATTTCAGGTGAAATCCAGACAATTGAAGATGGGCATATCAGAGCTAACGCCACCTCTACCTTAATATT**
 76 PheProGluLeuGlnValLeuAspLeuSerArgCysGluIeGlnThrIleGluAspGlyAlaTyrGlnSerLeuSerHisLeuSerThrLeuIleLe
 2001 **GACAGGAAACCCATCCAGAGTTAGCCCTGGAGCCTTCTGACTATCAAGTTACAGAAGCTGTGGCTGTGAGACAAATCTAGCATTCTAGAG**
 109 uThrGlyAsnProIleGlnSerLeuAlaLeuGlyAlaPheSerGlyLeuSerLeuGlnLeuValAlaValGluThrAsnLeuAlaSerLeuGlu
 2101 **AACTCCCCATTGGACATCTAAAACCTTGAAGAGAACTTAAATGTCGCTCACAATCTTCAAATTCTACCTGAGTTTTCTAAATCTGACCA**
 143 AsnPheProIleGlyHisLeuLysThrLeuLysGluLeuAsnValAlaHisAsnLeuIleGlnSerPheLysLeuProGluTyrPheSerAsnLeuThrA
 2201 **ATCTAGAGTACTGGACCTTCCAGAACAGATTCAAAAGATTATTATTCAGACAGACTTGGGGTTCTACATCAAATGCCCTACTCAATCTCTTTAGA**
 176 snLeuGluTyrLeuAspLeuSerSerAsnLysIleGlnSerIleTyrCysThrAspLeuArgValLeuHisGlnMetProLeuLeuAsnLeuSerLeuAs
 2301 **CCTGCCCAGACCCATTGAACTTATCAACCAGGTGCAATTAAAGAAATTAGGCTTCATAAGCTGACTTAAAGAAATAATTGATAGTTAAATGTA**
 209 pLeuSerLeuAsnProMetAsnPhelIeGlnProGlyAlaPheLysGluIeArgLeuHisLysLeuThrLeuArgAsnAsnPheAspSerLeuAsnVal
 2401 **ATGAAAACCTGTATTCAAGCTGGCTGGTTAGAAGTCCATGCTTGGGAGAATTAGAAAGGAACTGGAAAAGTTGACAAATCTG**
 243 MetLysThrCysIleGlnGlyLeuAlaGlyLeuGluValHisArgLeuValLeuGlyGluPheArgAsnGluGlyAsnLeuGluLysPheAspLysSerA

EcoRI (2534)

2501 **CTCTAGAGGGCTGTGCAATTGACCATGAAAGAATTCCGATTAGCATACTTACTACCTCGATGATATTATTGACTTATTTAATTGTTGACAA**
 276 IaLeuGluGlyLeuCysAsnLeuThrIleGluGluPheArgLeuAlaTyrLeuAspTyrTyrLeuAspAspIleIleAspLeuPheAsnCysLeuThrAs
 2601 **TGTTTCTTCAATTCCCTGGTGAATGACTATTGAAAGGGTAAAGACTTTCTATAATTTCGATGGCAACATTAGATAATTAGTAAACTGTA**
 309 nValSerSerPheSerLeuValSerValIleIleGluArgValLysAspPheSerTyrAsnPheGlyTrpGlnHisLeuGluLeuValAsnCysLysPhe
 2701 **GGACAGTTCCCACATTGAAACCTCAAATCTCTCAAAGGCTACTTCAACAAAGGTGGAAATGCTTTTCAAGGTTGATCTACCAAGCCTTG**
 343 GlyGlnPheProThrLeuLysLeuLysSerLeuLysArgLeuThrPheThrSerAsnLysGlyGlyAsnAlaPheSerGluValAspLeuProSerLeuG
 2801 **AGTTTCTAGATCTCAGTAGAAATGGCTTGAATTCAAAAGGTTGCTGTTCTCAAAGTGAATTGGGACAACCAGCTAACATGTTAGTCTGAGCTCAA**
 376 IlePheLeuAspLeuSerArgAsnGlyLeuSerPheLysGlyCysCysSerGlnSerAspPheGlyThrThrSerLeuLysTyrLeuAspLeuSerPheAs
 2901 **TGGTGTATTACCATGACTTCAAACCTTGGGCTTAGAACAACTAGAACATCTGGATTTCAGCATTCACATTGAAACAAATGAGTGAATTGTTGAGT**
 409 nGlyValIleThrMetSerSerAsnPheLeuGlyLeuGluLeuGlyLeuHisSerAsnPheGlyInHisSerAsnLeuLysGlnMetSerGluPheSerVal
 3001 **TTCCATCACTCAGAACACTCATTACTGACATTCTCATACTCACACCAGAGTTGCTTCAATGGCTTGTGAGCTCTCGAAGTCT**
 443 PheLeuSerLeuArgAsnLeuIleTyrLeuAspIleSerHisThrHisThrArgValAlaPheAsnGlyIlePheAsnGlyLeuSerLeuGluVall

EcoRV (3145)

3101 **TGAAAATGGCTGCAATTCTTCCAGGAAAACCTCCCTCCAGATATCTTCACAGAGCTGAGAAACTGACCTCTGGACCTCTCTCAGTGTCAACTGGA**
 476 euLysMetAlaGlyAsnSerPheGlnGluAsnPheLeuProAspIlePheThrGluLeuArgAsnLeuThrPheLeuAspLeuSerGlnCysGlnLeuGI
 3201 **GCAGTTGCTCCAAACAGCATTAACTCACTCTCAGTACTAAATGAGCCACAACAACTCTTCAATTGGGATACGTTCTTATAAGTGT**
 509 uGlnLeuSerProThrAlaPheAsnSerLeuSerLeuGlnValLeuAsnMetSerHisAsnAsnPhePheSerLeuAspThrPheProTyrLysCys

6801 TTTCTACATTCCAAGGAGAGATTAAAGCAATTATTCATCTATAACTGTCAACACCAGTGAATCTCCAAGGCCAAGAACAGTTGGCGA
6802 63► ePheTyrI leProArgArgAspLeuLysGlnLeuTyrPheAsnLeuTyrI leThrValAsnThrMetAsnLeuProLysArgLysGluVal I leCysArg
6901 GGATCTGATGACGATTACTCTTTGCAGAGCTGTGAATACAACATATCATTCTCCTCAAGGAATAAAATTCTCAAGGGAA
6902 97► GlySerAspAspAspTyrSerPheCysArgAlaLeuLysGlyGluThrValAsnThrThrI leSerPheSerPheLysGlyI leLysPheSerLysGlyL
7001 AATACAAATGTGTTGGAGCTATTCTGGGAGCCAGAAGAAATGCTTTGCTGGAGTTGTCATCTCACACCAACCTAATTCAAATTAGCTAGG
7002 130► ysTyrLysCysValValGluAlaI leSerGlySerProGluGluMetLeuPheCysLeuGluPheVal I leLeuHisGlnProAsnSerAsn...
7101 AGCAGGTTCCCCAATGACACAAAACGTGCAACTGAAACTCCGCCTGGTCTTCCAGGTCTAGAGGGTAACACTTTGACTGCGTTGGCTCCACGCT

7201 CGATCCACTGGCGAGTGTAGTAACAGCACTGTTGCTCGTAGCGGAGCATGACGGCGTGGAACTCCTCCTGGTAACAAGGACCCACGGGCCAAAA

7301 GCCACGCCACACGGGCCGTATGTGCAACCCCAGCACGGCAGCTTACTGCGAAACCCACTTAAAGTGACATTGAAACTGGTACCCACACACTGG

7401 TGACAGGCTAAGGATGCCCTCAGGTACCCCGAGGTAACACCGCACACTCGGGATCTGAGAAGGGACTGGGCTTCTATAAAAGCGCTGGTTAAAAA

7501 GCTTCTATGCCCTGAATAGGTGACCGGAGGTGGCACCTTCCCTTGAATTACTGACCCATGAAATACACTGACTGTTGACAATTAAATCATCGGCATAG
7601 TATATCGGCATAGTATAATACGACTCACTAGGAGGGCCACCATGAAAGACCTTCAACATCTCAGCAGGATCTGGAGCTGGTGGAGGTGCCACTGAG
7602 1► MetLysThrPheAsnI leSerGlnGlnAspLeuGluValAlaThrGlu
7701 AAGATCACCATGCTCTATGAGGACAACAAGCACCAGTCGGGGGGCCATCAGGACCAAGACTGGGAGATCATCTCTGCTGTCACATTGAGGCTACA
7702 20► LysI leThrMetLeuTyrGluAspAsnLysHisHisValGlyAlaAlaI leArgThrLysThrGlyGluI leI leSerAlaValHisI leGluAlaTyri
7801 TTGGCAGGGTCACTGTCTGTGCTGAAGCCATTGGGCTGTGAGCAACGGGAGAAGGACTTTGACACCATTTGAGCTGTCAGGCACCCCTA
7802 53► leGlyArgValThrValCysAlaGluAlaI leAlaI leGlySerAlaValSerAsnGlyGlnLysAspPheAspThrI leValAlaValArgHisProTy
7901 CTCTGATGAGGTGGACAGATCCATCAGGGTGGTCAGCCCTGTGGCATGTGAGAGACTCATCTGACTATGCTCTGACTGCTTGTGCTCATTGAG
7902 86► rSerAspGluValAspArgSerI leArgValValSerProCysGlyMetCysArgGluLeul I leSerAspTyrAlaProAspCysPheValLeul I leGlu
8001 ATGAATGGCAAGCTGGTCAAAACACCATTGAGGAACCTCATCCCCCTCAAGTACACCAGGAACCTGAATTATCGTAGGATTATCCCTAATAC
8002 120► MetAsnGlyLysLeuValLysThrThrI leGluGluLeul IeProLeuLysTyrThrArgAsn...
8101 CTGCCACCCACTTTAACAGTGGGAAGAACGGTCTCAGAACTGTTGTTCAATTGGCATTAAAGTTAGTTAGTAAAGACTGGTTAATGATAAC

8201 AATGCATCGAAAACCTTCAGAAGGAAAGGAGAATGTTTGTGACCACTTGGTTCTTTGCGTGTGCAGTTTAAGTTAGTTAGTTAAAAT

8301 CAGTACTTTAACAGGAAACACTTGACCAAAATTGTCACAGAATTGAGACCCATTAAAAAGTTAAATGAGAAACCTGTGTTCTGGTCAA

8401 CACCGAGACATTAGGTGAAAGACATCTAATTCTGGTTTACGAATCTGAAACCTTCTGAAATGTAATTCTGAGTTAACACTCTGGTGGAGAATA

8501 GGGTTGTTCCCCACATAATTGGAAGGGAGGAATATCATTAAAGCTATGGGAGGGTTCTTGATTACAACACTGGAGAGAAATGCAGCATGTT

8601 GCTGATTGCCCTGTCATAAAACAGGCCAAAACGTCAGTCCTGGGTCATAGAAAGCTG
→